Conflict Of Interest
Schools spent $23 million to bring conflict-of-interest policies in line with regulations aimed at ensuring federally funded research is unbiased.
The CMS said the issues should be resolved this week and will not affect this month's deadline for companies to submit payment data from 2014.
FDA approves the first biosimilar, judge rules that FDA panel members had conflicts of interest, and a new venture will evaluate the effectiveness of digital health technologies.
Pew Charitable Trust's proposed conflict of interest guidelines could mean even less face time for sales reps and less industry money for CME programs.
A BMJ study finds that medical school gift bans make doctors less likely to prescribe a new drug. Also of note: consumers think money motivates some doctors' recommendations.
CMS issued its long-delayed final rule for collecting data on industry payments to physicians, ordering data collection to begin in August and asserting that the federal law preempts state laws.
GlaxoSmithKline's Dierdre Connelly peeled back the curtain on the company's sales force incentives revamp in a speech to the Pharmaceutical Regulatory and Compliance Congress, and pleaded for recognition that the industry had cleaned up the sketchy practices of the Blockbuster Era.
Medtronic rebuffed Senate Finance Committee charges that the company ghostwrote or influenced journal articles about its InFuse bone-growth product while conspiring to paper over adverse events from the treatment.
Physicians take pharma-sponsored clinical trials with a grain of salt, a study published in The New England Journal of Medicine has found.
Physicians are reconsidering their participation in industry-sponsored CME, fearful that their inclusion in Sunshine Act databases as having received payments from companies will tarnish their reputations and fuel perceptions of conflicts of interest, a survey has found.
The Senate Finance Committee is looking to crack down on unnecessary pain prescriptions and is using a money trail to do it.
Medical journal coverage of the question of physician-industry relationships is "unbalanced" and may be skewing public policy towards ever-more restrictive safeguards against industry influence.
The majority of physicians agrees that it's important to disclose to patients any financial relationships with drug and device companies but, research shows, there remains considerable rearguard sentiment to transparency.
Researchers analyzing the prevalence of ghostwriting in leading medical journals over more than a decade saw a decline but found inappropriate authorship remained all too common.
Most US family medicine resident programs have limits on drug industry interaction with doctors, and a quarter shun doctor-company contacts altogether, said a survey by Georgetown University Medical Center and the American Medical Student Association.
Yale School of Medicine, which created conflict-of-interest guidelines years ago, has made them binding for physicians in its faculty practice.
ACCME: Peer review, plus other provider controls, enable industry employees to present original research in CMEJune 29, 2010
Several months' worth of dialogue, at times public and heated, between physician groups like the American Heart Association and the ACCME, has resulted in new guidance from the regulator of continuing medical education: Industry scientists, who had been barred from presenting original product-related research at for-credit talks, may now do so as long as provider controls ensure they have zero control over the content.
A policy barring pharmaceutical industry employees from giving continuing medical education talks at meetings has elicited strong opposition from physician leaders.
The nation's biggest funder of biomedical research has proposed several changes to its rules governing when and how investigators should disclose financial interests from industry.
Medical society journals must ban ghostwritten articles and cannot place ads for drugs next to editorial content discussing those products or their makers under a sweeping ethics code signed by several major medical societies.
The FDA announced a proposal to disclose more information about financial interests among its advisory committee members, while the agency's commissioner, Margaret Hamburg, offered some advice of her own, outlining steps for recruiting needed experts who have financial conflicts.
Thanks to the work of lobbyists, marketing research-related payments are explicitly excluded from Sunshine legislation enacted Tuesday as part of the healthcare overhaul. But the exclusion may not always apply.
Conflict-of-interest rules announced by New Jersey's Division of Consumer Affairs last week would seem to have mixed prospects under an incoming Republican administration.
Researchers submitting manuscripts to many medical journals will have to fill out a more probing disclosure form aimed at exposing potential conflicts of interest.
A Medscape-sponsored survey of a million physicians participating in online CME found that fewer than 1% perceived bias, regardless of whether or not it was commercially-supported.
The Accreditation Council for Continuing Medical Education is a toothless watchdog and should be abolished, said Cleveland Clinic's Dr. Steven Nissen at a Senate Committee on Aging hearing.
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.